These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 27770825)

  • 1. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
    Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
    Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose irinotecan improves advanced lupus nephritis in mice potentially by changing DNA relaxation and anti-double-stranded DNA binding.
    Frese-Schaper M; Keil A; Steiner SK; Gugger M; Körner M; Kocher GJ; Schiffer L; Anders HJ; Huynh-Do U; Schmid RA; Frese S
    Arthritis Rheumatol; 2014 Aug; 66(8):2259-69. PubMed ID: 24729466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis.
    Keil A; Frese-Schaper M; Steiner SK; Körner M; Schmid RA; Frese S
    Arthritis Rheumatol; 2015 Jul; 67(7):1858-67. PubMed ID: 25779651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
    Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
    Moser K; Kalies K; Szyska M; Humrich JY; Amann K; Manz RA
    Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
    J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.
    Frese-Schaper M; Zbaeren J; Gugger M; Monestier M; Frese S
    J Immunol; 2010 Feb; 184(4):2175-82. PubMed ID: 20083657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
    Schmidt T; Paust HJ; Krebs CF; Turner JE; Kaffke A; Bennstein SB; Koyro T; Peters A; Velden J; Hünemörder S; Haag F; Steinmetz OM; Mittrücker HW; Stahl RA; Panzer U
    Arthritis Rheumatol; 2015 Feb; 67(2):475-87. PubMed ID: 25385550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent Fasting Aggravates Lupus Nephritis through Increasing Survival and Autophagy of Antibody Secreting Cells in MRL/lpr Mice.
    Hong SM; Lee J; Jang SG; Song Y; Kim M; Lee J; Cho ML; Kwok SK; Park SH
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pim-1 as a Therapeutic Target in Lupus Nephritis.
    Fu R; Xia Y; Li M; Mao R; Guo C; Zhou M; Tan H; Liu M; Wang S; Yang N; Zhao J
    Arthritis Rheumatol; 2019 Aug; 71(8):1308-1318. PubMed ID: 30791224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.
    Jiang C; Zhao ML; Scearce RM; Diaz M
    Arthritis Rheum; 2011 Apr; 63(4):1086-96. PubMed ID: 21225690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
    Lu LD; Stump KL; Wallace NH; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Mason JL; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
    J Immunol; 2011 Oct; 187(7):3840-53. PubMed ID: 21880982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice.
    Yang J; Li Q; Yang X; Li M
    Mol Med; 2015 Apr; 21(1):364-70. PubMed ID: 25902303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALW peptide ameliorates lupus nephritis in MRL/lpr mice.
    Wang H; Lu M; Zhai S; Wu K; Peng L; Yang J; Xia Y
    Arthritis Res Ther; 2019 Dec; 21(1):261. PubMed ID: 31791413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models.
    Sugahara K; Maeda Y; Shimano K; Murase M; Mochiduki S; Takemoto K; Kakimoto T; Utsumi H; Oshita K; Kataoka H
    J Immunol Res; 2019; 2019():5821589. PubMed ID: 31930150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
    Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
    Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
    J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
    Pérez de Lema G; Maier H; Franz TJ; Escribese M; Chilla S; Segerer S; Camarasa N; Schmid H; Banas B; Kalaydjiev S; Busch DH; Pfeffer K; Mampaso F; Schlöndorff D; Luckow B
    J Am Soc Nephrol; 2005 Dec; 16(12):3592-601. PubMed ID: 16267157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
    Choi JY; Gao W; Odegard J; Shiah HS; Kashgarian M; McNiff JM; Baker DC; Cheng YC; Craft J
    Arthritis Rheum; 2006 Oct; 54(10):3277-83. PubMed ID: 17009262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.